Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review found inconclusive evidence on the effectiveness of botulinum toxin for treating alopecia and highlighted the need for further prospective randomized controlled trials.

This article reviews the literature on the off-label use of botulinum toxin for dermatological conditions, highlighting its potential effectiveness in treating rosacea, anal fissures, Raynaud phenomenon, hypertrophic scars, keloids, and hidradenitis suppurativa.

This review discusses the pathogenesis and management of hidradenitis suppurativa, examining conventional treatments and exploring botulinum toxin type A as a potential therapeutic option, but it reports no new clinical results.

This review discusses evidence-based complementary strategies for enhancing hair regrowth after post-COVID-19 telogen effluvium and reports no new clinical results.

In this case report, pulsed radiofrequency neuromodulation provided over 80% pain relief for five months in a patient with chronic lesser occipital nerve pain after other treatments failed.

This systematic review of five studies found that intradermal and intramuscular botulinum toxin injections showed promising hair growth outcomes for men with androgenic alopecia, but emphasizes caution due to a lack of control groups and small sample sizes.

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

In this systematic review and meta‐analysis, botulinum toxin monotherapy was found to significantly increase hair density in patients with androgenetic alopecia, with optimal effects observed using a 100-unit dose every six months. These findings suggest potential efficacy but should be confirmed in larger, placebo-controlled trials.

Botulinum toxins show promise in treating various conditions, but more research is needed for hair and scalp disorders.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.

In this randomized, controlled, clinical trial, the researchers found that injectable botulinum toxin did not promote hair growth in men with androgenetic alopecia over 12 or 24 weeks, showing no benefit in improving hair density compared to placebo.

This study found that both intradermal botulinum toxin A and intradermal minoxidil were equally effective for treating androgenetic alopecia, showing improvement in hair count with advantages like minimal invasiveness and absence of major side effects; minoxidil was also noted to be more cost-effective.

This study found that in male patients with androgenetic alopecia, combining botulinum toxin type A with 5% Minoxidil significantly improved hair growth, patient satisfaction, and quality of life over six months, compared to using Minoxidil alone, without causing adverse effects.

This study observed that combining botulinum toxin type A with Minoxidil significantly promoted hair growth, improved quality of life, and enhanced patient satisfaction in male androgenetic alopecia patients at 4 and 6 months, with no adverse effects compared to using Minoxidil alone.

This review reported on botulinum toxin's potential in treating dermatological conditions like hidradenitis suppurativa, rosacea, androgenetic alopecia, plaque psoriasis, and primary hyperhidrosis, highlighting initial efficacy but indicating a need for controlled trials to confirm safety and effectiveness.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

This paper reviews the effectiveness and side effects of various treatments for androgenetic alopecia, telogen effluvium, and alopecia areata, emphasizing the importance of discussing each option's costs, benefits, and risks with patients.

This systematic review concluded that mesotherapy shows potential for improving hair growth outcomes, yet lacks standardized regimens and requires further large-scale trials to establish its efficacy and safe use.

In this study, researchers reported that conventional treatments for folliculitis decalvans, which include steroids and antibiotics, are often ineffective, with many patients experiencing frequent recurrences of this scarring scalp disorder.

This chapter discusses the potential therapeutic applications of Botulinum toxin for various non-cosmetic skin conditions, such as acne, rosacea, and hyperhidrosis, highlighting case reports and some randomized controlled trials that indicate promise in alleviating discomfort, inflammation, and excessive sweating.

This extended abstract discusses various treatments for alopecia, including low-level light therapy, which has shown promise but requires further research to establish effectiveness, especially in combination with other therapies.

In this study, intradermal injection of botulinum toxin type A significantly increased hair count and improved physician-assessed hair condition in men with male pattern baldness after 24 weeks, with no serious adverse events reported beyond temporary local pain and redness.

This report describes a case of sclero-atrophy localized to the frontal scalp following an injection of botulinum toxin type A, which has not been previously documented in the literature.

Botulinum toxin injections can reduce hair loss and stimulate new hair growth in some men with male pattern baldness.

This study introduced a customizable ELISA for detecting antibodies against botulinum neurotoxin that matches or surpasses other tests in sensitivity and allows for more efficient and animal-friendly testing when combined with the hemidiaphragm assay.

Botulinum toxin-A injections in the scalp can reduce hair loss and promote new hair growth in men with certain types of baldness.

Botulinum toxin-A may increase hair growth and reduce hair loss in men with baldness, and injecting near blood vessels can improve pain relief and last longer.

In this study, mouse sebaceous glands were found to require nerves for growth during active hair cycles, suggesting a nerve-dependent sebaceous gland cycle coordinated with hair growth.